JP7862138B2 - 改変アデノウイルス - Google Patents

改変アデノウイルス

Info

Publication number
JP7862138B2
JP7862138B2 JP2020543282A JP2020543282A JP7862138B2 JP 7862138 B2 JP7862138 B2 JP 7862138B2 JP 2020543282 A JP2020543282 A JP 2020543282A JP 2020543282 A JP2020543282 A JP 2020543282A JP 7862138 B2 JP7862138 B2 JP 7862138B2
Authority
JP
Japan
Prior art keywords
cancer
adenovirus
modified
αvβ6
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020543282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513843A (ja
JP2021513843A5 (enExample
Inventor
パーカー，アラン
ウーシ－ケルトゥラ，ハンニ
Original Assignee
ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド filed Critical ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド
Publication of JP2021513843A publication Critical patent/JP2021513843A/ja
Publication of JP2021513843A5 publication Critical patent/JP2021513843A5/ja
Priority to JP2023191972A priority Critical patent/JP2024020345A/ja
Priority to JP2025025180A priority patent/JP2025081522A/ja
Application granted granted Critical
Publication of JP7862138B2 publication Critical patent/JP7862138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020543282A 2018-02-16 2019-02-13 改変アデノウイルス Active JP7862138B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023191972A JP2024020345A (ja) 2018-02-16 2023-11-10 改変アデノウイルス
JP2025025180A JP2025081522A (ja) 2018-02-16 2025-02-19 改変アデノウイルス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1802539.5A GB201802539D0 (en) 2018-02-16 2018-02-16 Modified adenoviruses
GB1802539.5 2018-02-16
PCT/GB2019/050380 WO2019158914A1 (en) 2018-02-16 2019-02-13 Modified adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191972A Division JP2024020345A (ja) 2018-02-16 2023-11-10 改変アデノウイルス

Publications (3)

Publication Number Publication Date
JP2021513843A JP2021513843A (ja) 2021-06-03
JP2021513843A5 JP2021513843A5 (enExample) 2023-06-01
JP7862138B2 true JP7862138B2 (ja) 2026-05-19

Family

ID=61783770

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020543282A Active JP7862138B2 (ja) 2018-02-16 2019-02-13 改変アデノウイルス
JP2023191972A Pending JP2024020345A (ja) 2018-02-16 2023-11-10 改変アデノウイルス
JP2025025180A Pending JP2025081522A (ja) 2018-02-16 2025-02-19 改変アデノウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023191972A Pending JP2024020345A (ja) 2018-02-16 2023-11-10 改変アデノウイルス
JP2025025180A Pending JP2025081522A (ja) 2018-02-16 2025-02-19 改変アデノウイルス

Country Status (16)

Country Link
US (1) US12318418B2 (enExample)
EP (1) EP3737403B1 (enExample)
JP (3) JP7862138B2 (enExample)
KR (1) KR102687425B1 (enExample)
CN (2) CN118834841A (enExample)
AU (1) AU2019220607B2 (enExample)
CA (1) CA3090859C (enExample)
DK (1) DK3737403T5 (enExample)
ES (1) ES2968387T3 (enExample)
FI (1) FI3737403T3 (enExample)
GB (1) GB201802539D0 (enExample)
IL (1) IL276535B2 (enExample)
PL (1) PL3737403T3 (enExample)
PT (1) PT3737403T (enExample)
SG (1) SG11202007470QA (enExample)
WO (1) WO2019158914A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081522A (ja) * 2018-02-16 2025-05-27 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 改変アデノウイルス

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
WO2021205364A1 (en) * 2020-04-07 2021-10-14 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered oncolytic adenovirus
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
GB202214580D0 (en) 2022-10-04 2022-11-16 Univ College Cardiff Consultants Ltd Adenoviral vector therapy
GB202314435D0 (en) 2023-09-20 2023-11-01 Univ College Cardiff Consultants Ltd Modified adenovirus
CN121203037B (zh) * 2025-09-26 2026-05-12 北京因诺惟康医药科技有限公司 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525166A (ja) 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子
US20110104788A1 (en) 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
ES2367227T3 (es) * 2007-03-14 2011-10-31 Institut Catala D'oncologia Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer.
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP3247807B1 (en) 2015-01-20 2020-12-16 Adcure Biotechnologies, LLC. Detargeted adenovirus variants and related methods
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525166A (ja) 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子
US20110104788A1 (en) 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRADSHAW AC. et al., Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses, J Control Release, 2012年, Vol. 164, p. 394-402
UUSI-KERTTULA H. et al., Atropism-modified,αvβ6 integrin-selective adenoviral vector for epithelial ovarian cancer therapies, Human Gene Therapy, 2017年, Vol. 28, no. 8, p. A11「FB03」
UUSI-KERTTULA H. et al., Pseudotyped ανβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies, Oncotarget, 2016年, 発行日, Vol. 7, No. 19, p. 27926-27937

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025081522A (ja) * 2018-02-16 2025-05-27 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 改変アデノウイルス

Also Published As

Publication number Publication date
ES2968387T3 (es) 2024-05-09
CA3090859C (en) 2025-04-01
IL276535B1 (en) 2025-03-01
KR102687425B1 (ko) 2024-07-22
IL276535B2 (en) 2025-07-01
JP2024020345A (ja) 2024-02-14
JP2025081522A (ja) 2025-05-27
IL276535A (en) 2020-09-30
PL3737403T3 (pl) 2024-03-18
PT3737403T (pt) 2024-01-24
WO2019158914A1 (en) 2019-08-22
DK3737403T5 (da) 2024-08-26
JP2021513843A (ja) 2021-06-03
FI3737403T3 (fi) 2024-01-17
SG11202007470QA (en) 2020-09-29
CA3090859A1 (en) 2019-08-22
EP3737403A1 (en) 2020-11-18
CN112020368A (zh) 2020-12-01
AU2019220607A1 (en) 2020-09-17
CN118834841A (zh) 2024-10-25
EP3737403B1 (en) 2024-01-03
CN112020368B (zh) 2024-07-12
US20210100855A1 (en) 2021-04-08
KR20200122346A (ko) 2020-10-27
DK3737403T3 (da) 2024-01-22
US12318418B2 (en) 2025-06-03
AU2019220607B2 (en) 2024-02-15
GB201802539D0 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
CN112020368B (zh) 修饰的腺病毒
US11419926B2 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
EP2486137B1 (en) Replication-competent ad11p based viral vectors
US9809803B2 (en) Mitogen-activated protein kinase-dependent recombinant vaccinia virus (MD-RVV) and use thereof
JP5618896B2 (ja) 新規アデノウイルス、それをコードする核酸及びその使用
CN107787364A (zh) 用于治疗癌症的治疗组合物及使用方法
PT2293804E (pt) Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação
JP2015051018A (ja) キメラアデノウイルスキャプシドタンパク質
WO2012163119A1 (zh) 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
WO2019201192A1 (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
WO2002072027A2 (en) Oncolytic rna replicons
HK40030481A (en) Modified adenoviruses
HK40030481B (en) Modified adenoviruses
Stepanenko et al. Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/SPAM1-armed oncolytic adenovirus Ad5Δ24RGD
JP2024512985A (ja) 改変アデノウイルス
CN117025674A (zh) 一种重组溶瘤病毒及制备方法与应用
WO2024074825A1 (en) Adenoviral vector therapy
van Winkel CRAd with capsid incorporated mesothelin for higher anti-tumor immunization
Man et al. The Novel Oncolytic Adenoviral Mutant Ad5-3D-A20T Retargeted to avb6 Integrins Efficiently Eliminates Pancreatic Cancer Cells
Coughlan Transductional retargeting of human adenovirus type 5 to ανβ6 integrin for cancer gene therapy
Pool et al. 656. Possible Cell Cycle Dependence for Efficient Transfection of ransfection of ransfection of Acute Myeloblastic Leukaemia Blasts Acute Myeloblastic Leukaemia Blasts with Adenoviral T Adenoviral T Adenoviral Type 5 Vectors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231219

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862138

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150